Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 5, 2025
Reporting Period: First Quarter ended March 31, 2025
This filing serves as a notification that the company has announced its financial results for the first quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document only confirms the announcement of results for the period ended March 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the information in this report, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2025) for actual revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the full press release.
- Check for any updated full-year guidance or clinical trial milestones mentioned in the attached exhibit.
- Confirm the status of the company's cash position and debt obligations in the detailed financial tables.